Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo

Harada,Koji; Ferdous,Tarannum; Harada,Toyoko; Takenawa,Takanori; Ueyama,Yoshiya

doi:10.3892/ol.2017.6602

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo

Authors:
- Koji Harada
- Tarannum Ferdous
- Toyoko Harada
- Takanori Takenawa
- Yoshiya Ueyama
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755‑8505, Japan
Published online on: July 18, 2017 https://doi.org/10.3892/ol.2017.6602
Pages: 3349-3356
Copyright: © Harada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gimeracil or 5-chloro-2,4‑dihydroxypyridine (CDHP) enhances the antitumor effects of 5‑fluorouracil (5‑FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5‑FU. CDHP, as part of a combination therapy, was also reported to exert a radiosensitizing effect. Therefore, CDHP may have underlying mechanisms of action other than DPD inhibition. The focus of the present study was to investigate the antitumor effects of CDHP and cisplatin (CDDP) combination treatment in vitro and in vivo against oral squamous cell carcinoma (OSCC) tumors. The inhibitory growth effects of CDHP and/or CDDP treatment on SAS and HSC2 cells were examined using an MTT assay. The expression levels of DNA double strand break repair proteins, including Ku70, DNA‑dependent‑protein kinase catalytic subunit (DNA‑PKcs), Rad50 and Rad51 in CDHP and/or CDDP‑treated cells were detected using western blotting. Nude mice with SAS or HSC2 tumors were treated with CDHP (administered orally 7 times/week) and/or CDDP (administered by intraperitoneal injection once/week) for 2 weeks. Combined treatment of CDHP and CDDP significantly suppressed the growth of SAS and HSC2 cells in vitro and that of tumors in vivo compared with the effects caused by single drug only or control treatments. Western blotting demonstrated that the expression levels of Ku70, DNA‑PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment. Immunohistochemistry also identified that the expression of DNA double strand break repair proteins was downregulated in tumors treated with CDHP and CDDP combination treatment compared with that of tumors treated with CDDP alone or control. The results of the current study suggest that CDHP may be responsible for enhancing the antitumor effects of CDDP by suppressing the DNA double strand break repair system. Therefore, the combination of CDHP and CDDP may be a potential effective option for OSCC treatment.

View Figures

View References

1	Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, Weaver A and Al-Sarraf M: Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 66:471–474. 1982.PubMed/NCBI
2	Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Yamane H, Homma A and Tomita T: Phase I/II Study of S-1 plus Cisplatin Combination Chemotherapy in Patients with Advanced/Recurrent Head and Neck Cancer. Jpn J Clin Oncol. 40:214–221. 2010. View Article : Google Scholar : PubMed/NCBI
3	Fujii M: Combination therapy with S-1 and CDDP for head and neck cancer. Gan To Kagaku Ryoho. 33:(Suppl 1). S150–S154. 2006.(In Japanese).
4	Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
5	Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, et al: Antitumor effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
6	Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn J Cancer Res. 78:748–755. 1987.PubMed/NCBI
7	Inuyama Y, Kida A, Tsukuda M, Kohno N and Satake B: S-1 Cooperative Study Group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho. 28:1381–1390. 2001.(In Japanese). PubMed/NCBI
8	Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T and Ryoke K: Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs. 19:85–90. 2008. View Article : Google Scholar : PubMed/NCBI
9	Asaumi Y, Miyanaga T, Hosokawa O, Nishida Y, Matsunaga T, Shimizu S, Tanaka N, Ito T, Sato Y, Hirano Y, et al: Effectiveness of postoperative adjuvant chemotherapy using S-1 plus CDDP for type 4 gastric cancer. Gan To Kagaku Ryoho. 40:323–325. 2013.(In Japanese). PubMed/NCBI
10	Rino Y, Murakami H, Yukawa N, Wada N, Oshima T, Matsuura H, Sugano N, Arai H, Masuda M and Imada T: Feasibility of S-1/CDDP therapy for outpatients with advanced gastric cancer. Gan To Kagaku Ryoho. 36:1829–1831. 2009.(In Japanese). PubMed/NCBI
11	Fujii M: Combination therapy with S-1 and CDDP for head and neck cancer. Gan To Kagaku Ryoho. 33:(Suppl 1). S150–S154. 2006.(In Japanese).
12	Uchida K, Hayashi K, Kuramochi H, Nakajima G, Inoue Y and Yamamoto M: Combination therapy of S-1 and CDDP for patients with colorectal cancer. J Cancer Res Clin Oncol. 133:841–846. 2007. View Article : Google Scholar : PubMed/NCBI
13	Fujii M, Sato H, Ogasawara T, Ando T, Tsujii S, Nagahori J, Komatsu Y and Matsuoka A: A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy. Gan To Kagaku Ryoho. 37:1987–1990. 2010.(In Japanese). PubMed/NCBI
14	Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T and Kurihara M: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res. 5:2620–2628. 1999.PubMed/NCBI
15	Scanlon KJ, Newman EM, Lu Y and Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 83:8923–8925. 1986. View Article : Google Scholar : PubMed/NCBI
16	Takagi M, Sakata K, Someya M, Tauchi H, Iijima K, Matsumoto Y, Torigoe T, Takahashi A, Hareyama M and Fukushima M: Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 96:259–266. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M and Fukushima M: Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 102:1712–1716. 2011. View Article : Google Scholar : PubMed/NCBI
18	Harada K, Ferdous T and Ueyama Y: Gimeracil exerts radiosensitizing effects on oral squamous cell carcinoma cells in vitro and in vivo. Anticancer Res. 36:5923–5930. 2016. View Article : Google Scholar : PubMed/NCBI
19	Takagi M, Sakata K, Someya M, Matsumoto Y, Tauchi H, Hareyama M and Fukushima M: The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization. Strahlenther Onkol. 188:255–261. 2012. View Article : Google Scholar : PubMed/NCBI
20	Rosenberg B: Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep. 59:589–598. 1975.PubMed/NCBI